TNFRSF17 and lymphoma: Its core advantage lies in its ability to precisely target tumor-specific antigens (such as CD19 and BCMA), demonstrating potent and durable cytotoxicity against certain hematologic malignancies that are resistant to or recurrent after traditional treatments, including B-cell leukemia, lymphoma, and multiple myeloma (21–23).